This transcript has been edited for clarity.
Hello. I'm Ileana Piña. I have recently taken a position at Thomas Jefferson University in Philadelphia. This is my blog.
I wanted to spend a little time today talking about the heart failure guidelines. We have been waiting for the American College of Cardiology/American Heart Association, and now Heart Failure Society of America, guidelines. All three organizations have collaborated here.
It also takes into consideration the definitions of heart failure that were published in the Journal of Cardiac Failure, which is the journal of the Heart Failure Society of America. That was published over a year ago, and I think it set the stage for these guidelines.
Certainly, the Europeans published their guidelines in the summer of 2021 at about the same time as the European Society of Cardiology (ESC) meeting.
We've all been wondering: Is it going to be the same, or are there any differences?
SGLT2 Inhibitors and ARNI
The ESC guidelines already included the sodium-glucose co-transporter 2 (SGLT2) inhibitors, and we had a consensus statement from the American College of Cardiology showing the benefits of the SGLT2 inhibitors and including them in the basis of care.
This is essentially one of the things that is now in these new guidelines, and that's the so-called pillars of care, which are made up of four individual drugs.
COMMENTARY
Key Points From the New Heart Failure Guidelines
Ileana L. Piña, MD, MPH
DisclosuresMay 04, 2022
This transcript has been edited for clarity.
Hello. I'm Ileana Piña. I have recently taken a position at Thomas Jefferson University in Philadelphia. This is my blog.
I wanted to spend a little time today talking about the heart failure guidelines. We have been waiting for the American College of Cardiology/American Heart Association, and now Heart Failure Society of America, guidelines. All three organizations have collaborated here.
It also takes into consideration the definitions of heart failure that were published in the Journal of Cardiac Failure, which is the journal of the Heart Failure Society of America. That was published over a year ago, and I think it set the stage for these guidelines.
Certainly, the Europeans published their guidelines in the summer of 2021 at about the same time as the European Society of Cardiology (ESC) meeting.
We've all been wondering: Is it going to be the same, or are there any differences?
SGLT2 Inhibitors and ARNI
The ESC guidelines already included the sodium-glucose co-transporter 2 (SGLT2) inhibitors, and we had a consensus statement from the American College of Cardiology showing the benefits of the SGLT2 inhibitors and including them in the basis of care.
This is essentially one of the things that is now in these new guidelines, and that's the so-called pillars of care, which are made up of four individual drugs.
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ileana L. Piña. Key Points From the New Heart Failure Guidelines - Medscape - May 04, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Ileana L. Piña, MD, MPH
Professor of Medicine/Cardiology/Heart Failure/Transplant; Quality Officer, Cardiovascular Line, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Clinical Professor of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan; Adjunct Professor of Epidemiology and Biostatistics, Population & Quantitative Health Sciences, Case Western University, Cleveland, Ohio
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health